Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H16O6.C10H21N3O |
| Molecular Weight | 587.6628 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)N1CCN(C)CC1.OC(=O)C2=CC3=C(C=CC=C3)C(CC4=C5C=CC=CC5=CC(C(O)=O)=C4O)=C2O
InChI
InChIKey=BDLFTHFBZRBSSL-UHFFFAOYSA-N
InChI=1S/C23H16O6.C10H21N3O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h1-10,24-25H,11H2,(H,26,27)(H,28,29);4-9H2,1-3H3
| Molecular Formula | C23H16O6 |
| Molecular Weight | 388.3695 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H21N3O |
| Molecular Weight | 199.2932 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf
Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
|||
| Curative | BANOCIDE Approved UseUsed for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
637 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
7220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIETHYLCARBAMAZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: |
Other AEs: Fever, Pruritus... Other AEs: Fever (63.6%) Sources: Pruritus (9.1%) Giddiness (9.1%) Joint ache (9.1%) |
2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: |
Other AEs: Fever, Nausea... Other AEs: Fever Sources: Nausea (27.3%) Vomiting (18.2%) Abdominal discomfort (9.1%) |
50 mg multiple, oral Studied dose |
unhealthy, 37 years |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (30%) Proteinuria (10%) Visual field constriction (20%) Optic nerve pallor (10%) Corneal opacity (90%) Anterior uveitis (10%) Chorioretinitis (10%) |
300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Sources: Papular urticarial eruption (70%) Proteinuria (30%) Visual field constriction (10%) Optic nerve pallor (20%) Corneal opacity (80%) Anterior uveitis (30%) Chorioretinitis (30%) |
6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 2, 5%) Sources: Nausea (grade 2, 2%) Vomiting (grade 2, 2%) Joint pain (grade 2, 2%) Eye swelling (grade 2, 2%) Rash (grade 2, 2%) Dyspnea (grade 2, 2%) |
8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
Other AEs: Fever, Headache... Other AEs: Fever (69%) Sources: Headache (65%) Vertigo (57%) Malaise (49%) Chills (45%) Joint pain (40%) Abdominal pain (37%) Chest pain (33%) Nausea (28%) Neck pain (24%) Vomiting (16%) Muscular pain (14%) Lymph node tenderness (38%) Epididymal tenderness (34%) Nodule (15%) Tinnitus (8%) Convulsion (2%) Eruption (<1%) Shock (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Fever | 63.6% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: |
| Giddiness | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: |
| Joint ache | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: |
| Pruritus | 9.1% | 6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: |
| Fever | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: |
|
| Vomiting | 18.2% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: |
| Nausea | 27.3% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: |
| Abdominal discomfort | 9.1% | 2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: |
unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: |
| Anterior uveitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Chorioretinitis | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Optic nerve pallor | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Proteinuria | 10% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Lymphadenopathy | 100% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Visual field constriction | 20% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Papular urticarial eruption | 30% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Corneal opacity | 90% | 50 mg multiple, oral Studied dose |
unhealthy, 37 years |
| Visual field constriction | 10% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Lymphadenopathy | 100% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Optic nerve pallor | 20% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Anterior uveitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Chorioretinitis | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Proteinuria | 30% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Papular urticarial eruption | 70% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Corneal opacity | 80% | 300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: |
unhealthy, 40 years |
| Dyspnea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Eye swelling | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Joint pain | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Nausea | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Rash | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Vomiting | grade 2, 2% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Fatigue | grade 2, 5% | 6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: |
| Muscular pain | 14% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Nodule | 15% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Vomiting | 16% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Convulsion | 2% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Neck pain | 24% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Nausea | 28% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Chest pain | 33% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Epididymal tenderness | 34% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Abdominal pain | 37% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Lymph node tenderness | 38% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Joint pain | 40% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Chills | 45% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Malaise | 49% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Vertigo | 57% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Headache | 65% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Fever | 69% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Tinnitus | 8% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Eruption | <1% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
| Shock | <1% | 8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: |
unhealthy |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [Activation >10 uM] | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Inhibition 10 uM] | ||||
| yes [Inhibition 10 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| likely | ||||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
|||
| no | no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lymphatic filariasis. | 2003-05-16 |
|
| Strategic options for global lymphatic filariasis elimination. | 2003-05 |
|
| Ensuring supplies of quality diethylcarbamazine citrate (DEC). | 2003-05 |
|
| Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India. | 2003-04 |
|
| Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis. | 2003-04 |
|
| Case report: intraocular localization of Mansonella perstans in a patient from south Chad. | 2003-03-11 |
|
| Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters. | 2003-03 |
|
| Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera. | 2003-03 |
|
| Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection. | 2003-01-01 |
|
| Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children. | 2003-01 |
|
| Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage. | 2003 |
|
| A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. | 2003 |
|
| Major progress toward eliminating lymphatic filariasis. | 2002-12-05 |
|
| Mass treatment to eliminate filariasis in Papua New Guinea. | 2002-12-05 |
|
| Modelling the epidemiology, transmission and control of lymphatic filariasis. | 2002-12 |
|
| Use of floating layers of polystyrene beads to control populations of the filaria vector Culex quinquefasciatus. | 2002-12 |
|
| Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis. | 2002-12 |
|
| Operational issues in the control of the vectors of Brugia. | 2002-12 |
|
| Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities. | 2002-12 |
|
| Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. | 2002-12 |
|
| Bancroftian filariasis: clinical parasitologic and serologic evaluation after 4 years applying two antifilarial regimens. | 2002-12 |
|
| Targeting of children in filariasis mass drug administration. | 2002-11-02 |
|
| [Asthenoscopic problems with a subconjunctival worm]. | 2002-11 |
|
| Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment. | 2002-11 |
|
| Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. | 2002-11 |
|
| Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender. | 2002-11 |
|
| Red blood cell antioxidant levels in Wuchereria bancrofti infection. | 2002-10 |
|
| Microfilaria in a thyroid nodule which resolved on treatment. | 2002-10 |
|
| Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae. | 2002-10 |
|
| Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials. | 2002-09-30 |
|
| The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole. | 2002-09 |
|
| The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia. | 2002-09 |
|
| The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination. | 2002-09 |
|
| Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis. | 2002-09 |
|
| The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt. | 2002-08 |
|
| New goals set for filariasis elimination in India. | 2002-07 |
|
| Mass drug administration to treat lymphatic filariasis. | 2002-06-01 |
|
| Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India. | 2002-06 |
|
| Case 1-2002: Loa loa. | 2002-05-30 |
|
| Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy. | 2002-05-30 |
|
| Young male with pancytopenia: an unusual cause. | 2002-05 |
|
| Anthelmintics: a review. | 2002-04-20 |
|
| [Toxocariasis in Poznan region, Poland, in years 1990-2000]. | 2002 |
|
| [Technical measures of filariasis elimination in Tengzhou City]. | 2002 |
|
| Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. | 2002 |
|
| Subconjunctival Loa Loa worm: case report. | 2002 |
|
| Compliance with the mass chemotherapy program for lymphatic filariasis. | 2001-12 |
|
| Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review. | 2001-11 |
|
| Mass DEC campaign for filariasis in a hyper endemic district of West Bengal. | 2001-09 |
|
| A brief introduction to the research achievement on the strategy and technical measures for interrupting the transmission of lymphatic filariasis in China. | 2001 |
Sample Use Guides
Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:56:47 GMT 2025
by
admin
on
Mon Mar 31 17:56:47 GMT 2025
|
| Record UNII |
X8816G8TOP
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
X8816G8TOP
Created by
admin on Mon Mar 31 17:56:47 GMT 2025 , Edited by admin on Mon Mar 31 17:56:47 GMT 2025
|
PRIMARY | |||
|
56973-50-3
Created by
admin on Mon Mar 31 17:56:47 GMT 2025 , Edited by admin on Mon Mar 31 17:56:47 GMT 2025
|
PRIMARY | |||
|
DTXSID40205577
Created by
admin on Mon Mar 31 17:56:47 GMT 2025 , Edited by admin on Mon Mar 31 17:56:47 GMT 2025
|
PRIMARY | |||
|
13475824
Created by
admin on Mon Mar 31 17:56:47 GMT 2025 , Edited by admin on Mon Mar 31 17:56:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |